\nAkci\u011fer kanseri tedavisinde sotorasib<\/strong>, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n neler ba\u015farabilece\u011fini g\u00f6steren en \u00e7arp\u0131c\u0131 \u00f6rneklerden biri olarak \u00f6ne \u00e7\u0131k\u0131yor. \u00d6zellikle KRAS G12C mutasyonlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK)<\/strong> hastalar\u0131nda, hedefe y\u00f6nelik tedavinin yeni standard\u0131n\u0131 tan\u0131mlamaya aday bir molek\u00fcl konumunda. \nSotorasib, KRAS G12C mutasyonunu se\u00e7ici olarak inhibe eden, oral yoldan kullan\u0131lan bir k\u00fc\u00e7\u00fck molek\u00fcl<\/strong>d\u00fcr. KRAS, uzun y\u0131llar boyunca onkoloji literat\u00fcr\u00fcnde \u201cundruggable<\/strong>\u201d yani ila\u00e7la hedeflenemez kabul edilen bir onkogen olarak an\u0131l\u0131yordu. \nSotorasib, mutant KRAS G12C proteininin GDP ba\u011fl\u0131 inaktif formuna kovalent olarak ba\u011flanarak<\/strong> onu kal\u0131c\u0131 \u015fekilde devre d\u0131\u015f\u0131 b\u0131rak\u0131r. B\u00f6ylece h\u00fccre i\u00e7i RAS\u2013RAF\u2013MEK\u2013ERK sinyal yolaklar\u0131<\/strong> bask\u0131lan\u0131r, t\u00fcm\u00f6r h\u00fccrelerinin b\u00fcy\u00fcmesi ve hayatta kalma sinyalleri kesintiye u\u011frar ve t\u00fcm\u00f6r b\u00fcy\u00fcmesi yava\u015flar veya durur \nBu mekanizma, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 tasar\u0131m\u0131n\u0131n ne kadar hassas ve ak\u0131ll\u0131 hale geldi\u011finin etkileyici bir \u00f6rne\u011fi: Art\u0131k sadece t\u00fcm\u00f6r\u00fc de\u011fil, t\u00fcm\u00f6r\u00fc \u00e7al\u0131\u015ft\u0131ran molek\u00fcler \u201ckontak anahtar\u0131n\u0131\u201d<\/strong> hedefleyebiliyoruz.\n<\/p>\n \nSotorasib, g\u00fcncel klinik kullan\u0131mdaki yeri itibar\u0131yla \u00f6zellikle:\n<\/p>\n \n\u00f6nemli bir se\u00e7enek olarak konumlanm\u0131\u015ft\u0131r \nTedaviye ba\u015flamadan \u00f6nce mutlaka:\n<\/p>\n \nBu ki\u015fiselle\u015ftirilmi\u015f yakla\u015f\u0131m, klasik kemoterapiye k\u0131yasla daha se\u00e7ici<\/strong> ve \u00e7o\u011fu hastada daha tolere edilebilir<\/strong> bir tedavi profili sunma potansiyeline sahiptir.\n<\/p>\n \nSotorasib\u2019in etkinli\u011fi ve g\u00fcvenli\u011fi, \u00f6zellikle CodeBreaK 100<\/strong> ve CodeBreaK 200<\/strong> klinik \u00e7al\u0131\u015fmalar\u0131yla detayl\u0131 \u015fekilde incelenmi\u015ftir:\n<\/p>\n \n\u00d6ne \u00e7\u0131kan noktalar aras\u0131nda:\n<\/p>\n \nyer almaktad\u0131r. Bu veriler, sotorasib\u2019i KRAS G12C mutasyonlu KHDAK i\u00e7in ilk onayl\u0131 hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl<\/strong> ila\u00e7lardan biri haline getirmi\u015ftir.\n<\/p>\n \nHer g\u00fc\u00e7l\u00fc k\u00fc\u00e7\u00fck molek\u00fcl hedefe y\u00f6nelik ila\u00e7ta oldu\u011fu gibi, sotorasib tedavisinde de baz\u0131 yan etkiler<\/strong> g\u00f6r\u00fclebilir. Klinik \u00e7al\u0131\u015fmalarda en s\u0131k bildirilen yan etkiler \u015funlard\u0131r \nBu nedenle tedavi s\u00fcresince:\n<\/p>\n \nb\u00fcy\u00fck \u00f6nem ta\u015f\u0131r. Yan etkilerin \u00e7o\u011fu, do\u011fru izlem ve zaman\u0131nda m\u00fcdahale ile y\u00f6netilebilir niteliktedir.\n<\/p>\n \nSotorasib, sadece KRAS G12C mutasyonlu akci\u011fer kanseri i\u00e7in bir tedavi se\u00e7ene\u011fi sunmakla kalm\u0131yor; ayn\u0131 zamanda \u201czor hedefli\u201d onkogenlerin<\/strong> bile k\u00fc\u00e7\u00fck molek\u00fcllerle yakalanabilece\u011fini kan\u0131tl\u0131yor. \nG\u00fcncel ara\u015ft\u0131rmalar, sotorasib\u2019in:\n<\/p>\n \nkombinasyon tedavileri<\/strong> i\u00e7inde kullan\u0131m\u0131n\u0131 da de\u011ferlendiriyor \nSotorasib, KRAS G12C mutasyonlu akci\u011fer kanseri tedavisinde paradigmay\u0131 de\u011fi\u015ftiren<\/strong> k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan biri olarak t\u0131pta yerini \u015fimdiden ald\u0131. \nK\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n bu t\u00fcr hedef odakl\u0131 yakla\u015f\u0131mlarla<\/strong> birle\u015fmesi, \u00f6n\u00fcm\u00fczdeki d\u00f6nemde akci\u011fer kanseri ba\u015fta olmak \u00fczere pek \u00e7ok kanser t\u00fcr\u00fcnde \u00e7ok daha ki\u015fiselle\u015ftirilmi\u015f, etkili ve y\u00f6netilebilir<\/strong> tedavi stratejilerinin kap\u0131s\u0131n\u0131 aral\u0131yor. \nSotorasib, KRAS G12C mutasyonlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri<\/strong> tedavisinde kullan\u0131lan, a\u011f\u0131zdan al\u0131nan hedefe y\u00f6nelik bir k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6r<\/strong>d\u00fcr. Mutant KRAS G12C proteininin inaktif formuna kovalent ba\u011flanarak onu kal\u0131c\u0131 olarak inhibe eder ve t\u00fcm\u00f6r h\u00fccrelerinin b\u00fcy\u00fcmesini bask\u0131lar \nSotorasib, \u00f6zellikle ileri evre KRAS G12C mutasyonlu KHDAK<\/strong> hastalar\u0131nda, daha \u00f6nce sistemik tedavi (kemoterapi, imm\u00fcnoterapi vb.) alm\u0131\u015f ve hastal\u0131\u011f\u0131 ilerlemi\u015f ki\u015filer i\u00e7in uygundur. \nEn s\u0131k bildirilen yan etkiler aras\u0131nda ishal, bulant\u0131, kusma, karaci\u011fer enzimlerinde y\u00fckselme, yorgunluk ve i\u015ftahs\u0131zl\u0131k<\/strong> bulunur. \nSotorasib, do\u011frudan KRAS G12C mutasyonunu hedefledi\u011fi<\/strong> i\u00e7in klasik kemoterapiden \u00e7ok daha spesifik<\/strong> bir mekanizmaya sahiptir. \nEvet. Devam eden klinik ara\u015ft\u0131rmalarda sotorasib; imm\u00fcnoterapi ajanlar\u0131<\/strong> ve di\u011fer sinyal yolu inhibit\u00f6rleri<\/strong> ile kombinasyon halinde de\u011ferlendirilmektedir. Sotorasib, KRAS G12C mutasyonlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde hedefe y\u00f6nelik tedavide \u00e7\u0131\u011f\u0131r a\u00e7an bir k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7t\u0131r. \u00c7al\u0131\u015fma mekanizmas\u0131, hangi hastalar i\u00e7in uygun oldu\u011fu, CodeBreaK klinik \u00e7al\u0131\u015fmalar\u0131 ve yan etkilerini anla\u015f\u0131l\u0131r bir dille ke\u015ffedin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[881,882,814,880,811,800,818,812],"class_list":["post-10330","post","type-post","status-publish","format-standard","hentry","category-molekul","tag-akciger-kanseri-tedavisi","tag-codebreak-100","tag-hedefe-yonelik-tedavi","tag-khdak","tag-kras-g12c","tag-kucuk-hucreli-disi-akciger-kanseri","tag-kucuk-molekul-ilaclar","tag-sotorasib"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10330"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10330\/revisions"}],"predecessor-version":[{"id":10331,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10330\/revisions\/10331"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nBu yaz\u0131da, sotorasib\u2019in \u00e7al\u0131\u015fma mekanizmas\u0131n\u0131, hangi hastalar i\u00e7in uygun oldu\u011funu, klinik \u00e7al\u0131\u015fma sonu\u00e7lar\u0131n\u0131 ve yan etki profilini; hem bilimsel hem de herkesin anlayabilece\u011fi, samimi bir dille ele alaca\u011f\u0131z.\n<\/p>\nSotorasib Nedir ve Neden \u201cOyun De\u011fi\u015ftirici\u201d G\u00f6r\u00fcl\u00fcyor?<\/h2>\n
\n\u00d6zellikle sigara \u00f6yk\u00fcs\u00fc olan KHDAK hastalar\u0131nda s\u0131k g\u00f6r\u00fclen KRAS G12C mutasyonu, klasik kemoterapi ve imm\u00fcnoterapilere ra\u011fmen tedavi zorluklar\u0131n\u0131n ba\u015f akt\u00f6rlerinden biriydi.\n<\/p>\n
\n(doi:10.1056\/NEJMoa1917239<\/a>).\n<\/p>\nHangi Hastalar \u0130\u00e7in Sotorasib Uygun?<\/h2>\n
\n
\n(doi:10.1056\/NEJMoa2103695<\/a>).\n<\/p>\n\n
Klinik \u00c7al\u0131\u015fmalarda Sotorasib: CodeBreaK Serisi Ne G\u00f6sterdi?<\/h2>\n
\n
\n (doi:10.1056\/NEJMoa1917239<\/a>).<\/li>\n
\n (doi:10.1056\/NEJMoa2103695<\/a>).<\/li>\n<\/ul>\n\n
Sotorasib Yan Etkileri: Nelere Dikkat Edilmeli?<\/h2>\n
\n(doi:10.1016\/j.ccell.2020.11.002<\/a>):\n<\/p>\n\n
\n
Gelece\u011fe Bak\u0131\u015f: Sotorasib ve K\u00fc\u00e7\u00fck Molek\u00fcl Hedefe Y\u00f6nelik Tedavilerin Yeni Dalgas\u0131<\/h2>\n
\nBu ba\u015far\u0131, di\u011fer KRAS mutasyonlar\u0131 (G12D, G12V vb.) ve farkl\u0131 onkojenik s\u00fcr\u00fcc\u00fc mutasyonlar i\u00e7in de benzer stratejilerin geli\u015ftirilmesine ilham veriyor.\n<\/p>\n\n
\n(doi:10.1038\/s41591-021-01355-4<\/a>).
\nAma\u00e7, hem diren\u00e7 geli\u015fimini azaltmak<\/strong> hem de tedavi etkinli\u011fini art\u0131rmak<\/strong>.
\n\u00d6n\u00fcm\u00fczdeki y\u0131llarda, molek\u00fcler profili detayl\u0131 \u00e7\u0131kar\u0131lm\u0131\u015f hastalar i\u00e7in tamamen ki\u015fiselle\u015ftirilmi\u015f k\u00fc\u00e7\u00fck molek\u00fcl kokteylleri<\/strong> g\u00f6rmemiz hi\u00e7 de uzak bir senaryo de\u011fil.\n<\/p>\nSonu\u00e7: K\u00fc\u00e7\u00fck Bir Molek\u00fcl, B\u00fcy\u00fck Bir D\u00f6n\u00fc\u015f\u00fcm<\/h2>\n
\nSpesifik hedefe kilitlenen, a\u011f\u0131zdan kullan\u0131lan ve molek\u00fcler d\u00fczeyde ince ayar yapan bu ila\u00e7; hem hasta konforu<\/strong> hem de tedavi ba\u015far\u0131s\u0131<\/strong> a\u00e7\u0131s\u0131ndan yeni bir d\u00f6nemin habercisi.\n<\/p>\n
\nBu nedenle sotorasib, sadece bir ila\u00e7 de\u011fil, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 tasar\u0131m\u0131n\u0131n nereye gidebilece\u011finin g\u00fc\u00e7l\u00fc bir i\u015faret fi\u015fe\u011fi.\n<\/p>\nKaynaklar (DOI)<\/h3>\n
\n
S\u0131k Sorulan Sorular: Sotorasib Hakk\u0131nda Merak Edilenler<\/h2>\n
Sotorasib nedir, ne i\u00e7in kullan\u0131l\u0131r?<\/h3>\n
\n(doi:10.1056\/NEJMoa1917239<\/a>).\n<\/p>\nSotorasib kimler i\u00e7in uygundur?<\/h3>\n
\nUygulama \u00f6ncesinde mutlaka t\u00fcm\u00f6r dokusu veya s\u0131v\u0131 biyopsi ile KRAS G12C mutasyonunun do\u011frulanmas\u0131<\/strong> gerekir
\n(doi:10.1056\/NEJMoa2103695<\/a>).\n<\/p>\nSotorasib\u2019in en s\u0131k g\u00f6r\u00fclen yan etkileri nelerdir?<\/h3>\n
\nD\u00fczenli kan testleri ve hekim kontrol\u00fc ile bu yan etkilerin \u00e7o\u011fu doz ayarlamas\u0131<\/strong> ve destek tedavilerle y\u00f6netilebilir
\n(doi:10.1016\/j.ccell.2020.11.002<\/a>).\n<\/p>\nSotorasib, kemoterapiden daha m\u0131 etkilidir?<\/h3>\n
\nBaz\u0131 \u00e7al\u0131\u015fmalarda doketaksel ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda daha iyi veya benzer progresyonsuz sa\u011fkal\u0131m ve daha y\u00f6netilebilir bir yan etki profili bildirilmi\u015ftir; ancak her hasta i\u00e7in bireysel de\u011ferlendirme \u015fartt\u0131r
\n(doi:10.1056\/NEJMoa2103695<\/a>).\n<\/p>\nSotorasib ba\u015fka ila\u00e7larla birlikte kullan\u0131labilir mi?<\/h3>\n
\nAma\u00e7, hem diren\u00e7 geli\u015fimini azaltmak<\/strong> hem de tedavi etkinli\u011fini art\u0131rmak<\/strong>t\u0131r
\n(doi:10.1038\/s41591-021-01355-4<\/a>).
\nG\u00fcncel klinik uygulamada kombinasyon se\u00e7enekleri mutlaka onkolo\u011funuzun rehberli\u011finde, k\u0131lavuzlar ve en g\u00fcncel veriler \u0131\u015f\u0131\u011f\u0131nda belirlenmelidir.<\/p>\n","protected":false},"excerpt":{"rendered":"